Generate Biomedicines and Zealand Pharma Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases
Generate Biomedicines official news-release RSS · Indexed industry source record · Source published: Tue Oct 13 2026 20:30:00 GMT+0000 (Coordinated Universal Time) · Indexed here: Tue Oct 13 2026 21:08:11 GMT+0000 (Coordinated Universal Time)
Saved source excerpt
Collaboration will combine Zealand Pharma’s expertise in metabolic health with Generate’s proprietary generative AI platform to create multispecific drug candidates with tailored biological functions Generate will receive $30M upfront, up to $35M in early preclinical milestones, and a total of up to $1.2B in milestones, plus tiered royalties for two initial programs, with an option to add a third
This is a cited excerpt from the source. Read the original link for the complete text. Automated indexing and topic classification do not constitute fact verification.